Firebrick Pharma LimitedASX: FRE

Firebrick Investor Update

· Issued by Firebrick Pharma Limited

Filed with ASX · · 3 pages · English

Summary by 6ix AI

The company plans to market Nasodine as a nasal antiseptic/disinfectant, with sales expected to begin in the following year. Firebrick remains committed to developing Nasodine for the common cold but will explore alternative study designs due to the issues encountered in the recent trial.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Firebrick Pharma Limited on 6ix

Earlier from Firebrick Pharma

Later from Firebrick Pharma

All Firebrick Pharma news releases